SSUMY Stock UPDATES Sumitomo Corp Sp ADR (SSUMY) 12.6800 09/10/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sumitomo Corp Sp ADR (SSUMY) 12.6800 $SSUMY

GE Wins Alstom Board Approval; Govt Seeking 20% Stake - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 1:25PM CDT
General Electric (GE) won unanimous approval of the French conglomerate Alstom's board to acquire its energy assets in a $16.9 billion deal, taking it a step closer to clinching its biggest acquisition ever.

GE Improves Alstom Power Bid, Siemens Follows Suit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 2:30PM CDT
Pulling the ball back in its court, General Electric (GE) made a strong comeback to counter the Siemens-Mitsubishi offer for Alstom's energy assets by updating its offer to buy the French engineering group's energy assets.

United Tech Amends Canada Deal, Reaffirms Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 5:30PM CDT
United Technologies (UTX) declared that Sikorsky has amended a contract agreement with the Canadian Government. The amended contract will allow Canada to replace its maritime fleet with 28 Sikorsky's CH148 Cyclone helicopters.

GE, CTSI to Build Cancer Network in India - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:50AM CDT
GE Healthcare recently formed a strategic partnership with Cancer Treatment Services International to launch a chain of 25 cancer care centres in India.

Falling Earnings Estimates Signal Weakness Ahead for Raven (RAVN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:49AM CDT
It may be a good decision to sell Raven as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.

Raven Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 3:00PM CDT
Zacks Investment Research has downgraded Raven to a Zacks Rank #5 (Strong Sell).

3M's China Growth at Triple Pace - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 3:30PM CDT
3M recently projected that sales in China will triple in the next five years compared to the rest of the world, driven by a huge demand for health and consumer products such as face masks and water filters.

GE's 2Q Operating Earnings Marginally Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 19, 10:38AM CDT
General Electric reported relatively disappointing second quarter 2013 results with operating earnings of $3.7 billion or 36 cents a share compared to $4.0 billion or 38 cents a share in the year-ago quarter.


Japan gives Myanmar $504M loan, forgives debt
By AYE AYE WIN - AP - Sun May 26, 5:14AM CDT
YANGON, Myanmar (AP) — Japan's government on Sunday extended its first loan to Myanmar in 26 years and canceled the remainder of the Southeast Asian country's debt, as Tokyo looks to re-establish strong economic ties with the former pariah nation.


Abe on 1st trip to Myanmar by Japan PM in 36 years
By AYE AYE WIN - AP - Fri May 24, 8:49AM CDT
YANGON, Myanmar (AP) — Prime Minister Shinzo Abe arrived in Myanmar on Friday on the first visit to the country by a Japanese leader in 36 years, as Tokyo bids to reassert its position as a top economic partner after decades of frosty relations with the previous military regime.

Deal signed to clear Myanmar debt, allow new loans
By AYE AYE WIN - AP - Sun Jan 27, 9:56PM CST
YANGON, Myanmar (AP) — The World Bank announced a long-awaited deal to allow Myanmar to clear part of its huge decades-old foreign debt, opening the door for new much-needed lending to jumpstart its lagging economy.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 34

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 44

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 41

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 39

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 31

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Knee Treatment with Overture's Latest System

Updated Category News Views 312

Full Commercial Launch of the OvertureTi Knee Resurfacing System Overture Orthopaedics is making headlines as it proudly announces the full commercial launch of its advanced OvertureTi Knee Resurfacing System. This medical device targets early osteoarthritis and cartilage defects effectively, presenting a breakthrough for patients seeking alternatives to traditional joint...

Continue Reading
Elis SA: Key Insights on Recent Share Buyback Activities

Updated Category News Views 130

Elis SA's Recent Share Buyback Activities Elis SA has made a mark with its recent trading activities associated with its own shares, particularly highlighting a series of transactions carried out during a specified period. Overview of the Buyback Program As part of its strategic financial planning, Elis has engaged in a buyback program that has garnered attention. The...

Continue Reading
Kevin O'Leary's Essential Advice for Startups on Content Investment

Updated Category News Views 262

O'Leary: Tools Are Cheap, But Talent Isn't Entrepreneur and "Shark Tank" star Kevin O'Leary emphasizes a critical insight for startups: while the cost of creating digital content has drastically reduced, the true value comes from the talent that produces it. O'Leary shared his thoughts in a recent video, indicating that although the cost of technology has significantly...

Continue Reading
The St. James Reinvents Lacrosse with Spencer Ford at the Helm

Updated Category News Views 237

The St. James Strengthens Lacrosse Initiatives In an exciting development, The St. James has appointed Spencer Ford as the new Director of Lacrosse, ushering in a transformative approach to lacrosse for both boys and girls. With a vast wealth of experience spanning nearly twenty years, Ford is not only a seasoned professional player but also an accomplished coach and...

Continue Reading
Hudbay Minerals Celebrates Permit Approval for Copper World

Updated Category News Views 119

Hudbay Minerals Receives Final Permit for Copper World Project Hudbay Minerals Inc. (TSX, NYSE: HBM), a prominent player in the mining industry, has taken a significant step forward by securing the final major permit necessary for its Copper World project in Arizona. This milestone not only enhances the company’s operational capacity but also solidifies its commitment...

Continue Reading